Samra Turajlić
Director of Cancer Research UK Manchester Institute | Cancer Dynamics Group Leader
Samra is the Director of Cancer Research UK Manchester Institute, a Consultant Medical Oncologist at the Christie and also leads the Cancer Dynamics research group. They apply evolutionary principles to predict the trajectory of individual cancers by studying the forces that shape cancer evolution with the aim of using this knowledge to improve patient outcomes.
About Professor Samra Turajlić
Samra Turajlić completed her undergraduate studies at Oxford University and her clinical training at UCL medical school. She gained a PhD in 2013 from Institute of Cancer Research in the field of melanoma genetics and targeted therapy resistance.
In 2014, she was awarded a Cancer Research UK Clinician Scientist Fellowship to study cancer evolution at the Francis Crick Institute. She completed her training in medical oncology in 2015 and was appointed a Consultant Medical Oncologist on the Skin and Urology Units at the Royal Marsden. She became an independent Group Leader at the Francis Crick Institute in 2019, and divided her time between the clinic and her lab.
In 2025 Samra became the Director of the Cancer Research UK Manchester Institute, where she is also a Senior Group Leader and Consultant Medical Oncologist at the Christie NHS Foundation Trust.
Prof Turajlic is the Chief Investigator of translational studies into melanoma and kidney cancer (TRACERx), and her research goal is to develop an evolutionary understanding of cancer for patient benefit. She is a member of the NCRI Bladder and Renal Cancer Clinical Studies Group, ESMO Faculty member for genitourinary cancers; and Scientific Committee member for ESMO, Molecular Analysis for Personalised Therapy, Kidney Cancer Association, and EORTC-NCI-AACR Symposia.
She is a Trustee of the Kidney Cancer Support Network and Melanoma Focus, and a Senior Editor at Macmillan Cancer Support. Prof Turajlic receives research funding from CRUK, Rosetrees Trust, the Royal Marsden Cancer Charity, and the RMH/ICR Biomedical Research Centre, among others.
Groups
Qualifications
- BA Physiological Sciences | 1999 | University of Oxford
- MBBS | 2002 | University College London
- MRCP | 2006 | Royal College of Physicians
- PhD | 2013 | Institute of Cancer Research
Interests
- Modelling cancer evolution
- Constraints of evolution
- Tracking evolution of melanoma through therapy resistance
Research Projects
Our vision for world leading cancer research in the heart of Manchester
We are a leading cancer research institute within The University of Manchester, spanning the whole spectrum of cancer research – from investigating the molecular and cellular basis of cancer, to translational research and the development of therapeutics.
Our collaborations
Bringing together internationally renowned scientists and clinicians
Scientific Advisory Board
Supported by an international Scientific Advisory Board
Why choose Cancer Research UK Manchester Institute?
The Cancer Research UK Manchester Institute, an Institute of The University of Manchester, is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org),
the largest independent cancer research organisation in the world.
We are partnered with The Christie NHS Foundation Trust, one of the largest cancer treatment centres in Europe, which is located adjacent to the CRUK MI Manchester Institute in South Manchester. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.
